여성에서의 건선: 관리와 치료 = Psoriasis in Women: Management and Treatment

다국어 초록 (Multilingual Abstract)

Psoriasis is a chronic inflammatory skin disease affecting 0.5~3% of the general population worldwide. About 50% of these patients are women and the majority of them have onset of disease before 40 years of age, coinciding with the reproductive years. The burden of psoriasis is particularly high for women in all domains of quality of life, which poses specific challenges for their treatment. However, well-established guidelines for the treatment of women of childbearing age are lacking. Because of immunomodulatory change in pregnancy, psoriasis activity often improves or stabilizes during pregnancy. But up to a quarter can experience disease worsening, and postpartum flares are common. Therefore, balancing the risk of treatment with the risk of uncontrolled disease is important. In this article, we review issues specific to treating women of childbearing age with psoriasis and recent guidelines for the treatment of psoriasis in women.

참고문헌 (Reference)

1 Bangsgaard N, "Treating Psoriasis During Pregnancy : Safety and Efficacy of Treatments" 16 : 389-398, 2015

2 Augustin M, "Topical long-term therapy of psoriasis with vitamin D₃ analogues, corticosteroids and their two compound formulations : position paper on evidence and use in daily practice" 12 : 667-682, 2014

3 Owczarek W, "The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation : a review of current clinical guidelines" 37 : 821-830, 2020

4 Lima XT, "The impact of psoriasis on pregnancy outcomes" 132 : 85-91, 2012

5 Salaffi F, "The healthrelated quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis : a comparison with a selected sample of healthy people" 7 : 25-, 2009

6 Wahl A, "The burden of psoriasis : a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms" 43 : 803-808, 2000

7 Grosen A, "The Influence of Methotrexate Treatment on Male Fertility and Pregnancy Outcome After Paternal Exposure" 23 : 561-569, 2017

8 Hyoun SC, "Teratogen update : methotrexate" 94 : 187-207, 2012

9 Torchinsky A, "TNF-alpha protects embryos exposed to developmental toxicants" 49 : 159-168, 2003

10 Butler DC, "Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation" 70 : 417.e1-417.e10, 2014

11 Murase JE, "Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy" 70 : 401.e1-401.e4, 2014

12 Nast A, "S3 Guideline for the treatment of psoriasis vulgaris, update-Short version part 1-Systemic treatment" 16 : 645-669, 2018

13 Bae YS, "Review of treatment options for psoriasis in pregnant or lactating women : from the Medical Board of the National Psoriasis Foundation" 67 : 459-477, 2012

14 Langley RG, "Psoriasis: epidemiology, clinical features, and quality of life" 64 (64): ii18-ii23, 2005

15 Rademaker M, "Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration" 59 : 86-100, 2018

16 Ruiz V, "Psoriasis in pregnancy : a review(I)" 105 : 734-743, 2014

17 Yang YW, "Psoriasis and pregnancy outcomes : a nationwide population-based study" 64 : 71-77, 2011

18 Boyd AS, "Psoriasis and pregnancy : hormone and immune system interaction" 35 : 169-172, 1996

19 Tauscher AE, "Psoriasis and pregnancy" 6 : 561-570, 2002

20 Bobotsis R, "Psoriasis and adverse pregnancy outcomes : a systematic review of observational studies" 175 : 464-472, 2016

21 Kaushik SB, "Psoriasis : which therapy for which patient : focus on special populations and chronic infections" 80 : 43-53, 2019

22 Canibaño B, "Pregnancy-related issues in women with multiple sclerosis : an evidence-based review with practical recommendations" 9 : 20-36, 2020

23 Cohen-Barak E, "Pregnancy outcomes in women with moderate-to-severe psoriasis" 25 : 1041-1047, 2011

24 Chi CC, "Pregnancy outcomes after maternal exposure to topical corticosteroids : a UK population-based cohort study" 149 : 1274-1280, 2013

25 Ben-David G, "Pregnancy outcome in women with psoriasis" 53 : 183-187, 2008

26 Ghanem ME, "Pregnancy outcome after renal allograft transplantation : 15 years experience" 121 : 178-181, 2005

27 Weber-Schoendorfer C, "Pregnancy outcome after TNF- inhibitor therapy during the first trimester : a prospective multicentre cohort study" 80 : 727-739, 2015

28 Seeger JD, "Pregnancy and pregnancy outcome among women with inflammatory skin diseases" 214 : 32-39, 2007

29 Kane SV, "Placental transport of immunoglobulins : a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy" 104 : 228-233, 2009

30 Harder E, "No increased risk of fetal death or prolonged time to pregnancy in women with psoriasis" 134 : 1747-1749, 2014

31 Nguyen C, "Multiple anomalies in a fetus exposed to low-dose methotrexate in the first trimester" 99 : 599-602, 2002

32 Ferreira C, "Management of psoriasis in pregnancy-a review of the evidence to date" 9 : 2020

33 Hawro M, "Lesions on the back of hands and female gender predispose to stigmatization in patients with psoriasis" 76 : 648-654.e642, 2017

34 Menter A, "Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies" 82 : 1445-1486, 2020

35 Simone IL, "Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies" 12 : 697974-, 2021

36 Petri M, "Immunosuppressive drug use in pregnancy" 36 : 51-56, 2003

37 Murase JE, "Hormonal effect on psoriasis in pregnancy and post partum" 141 : 601-606, 2005

38 Ryan C, "Genital psoriasis is associated with significant impairment in quality of life and sexual functioning" 72 : 978-983, 2015

39 Lesuis N, "Gender and the treatment of immune-mediated chronic inflammatory diseases : rheumatoid arthritis, inflammatory bowel disease and psoriasis : an observational study" 10 : 82-, 2012

40 Malek A, "Evolution of maternofetal transport of immunoglobulins during human pregnancy" 36 : 248-255, 1996

41 Nast A, "EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris-Part 2 : specific clinical and comorbid situations" 35 : 281-317, 2021

42 Bröms G, "Effect of Maternal Psoriasis on Pregnancy and Birth Outcomes : A Population-based Cohort Study from Denmark and Sweden" 98 : 728-734, 2018

43 Gudjonsson JE, "Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients--an analysis of 1019 HLA-C-and HLA-B-typed patients" 126 : 740-745, 2006

44 Mrowietz U, "Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis : a European expert consensus" 32 (32): 3-14, 2018

45 Gottlieb AB, "Clinical considerations for the management of psoriasis in women" 5 : 141-150, 2019

46 Smith CH, "British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 : a rapid update" 183 : 628-637, 2020

47 Smith CH, "British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017" 177 : 628-636, 2017

48 Lamarque V, "Analysis of 629 pregnancy outcomes in transplant recipients treated with Sandimmun" 29 : 2480-, 1997

49 David M, "Adverse effects of retinoids" 3 : 273-288, 1988